{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:51:09Z","timestamp":1788519069778,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.bbagen.2023.130414","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T21:30:12Z","timestamp":1686951012000},"page":"130414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Design, synthesis, in vitro and in silico evaluation of anti-colorectal cancer activity of curcumin analogues containing 1,3-diphenyl-1H-pyrazole targeting EGFR tyrosine kinase"],"prefix":"10.1016","volume":"1867","author":[{"given":"Nam Q.H.","family":"Doan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan T.K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen N.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagen.2023.130414_bb0005","first-page":"7","article-title":"Cancer statistics, 2022. CA cancer","volume":"72","author":"Siegel","year":"2022","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bbagen.2023.130414_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.bbagen.2023.130414_bb0015","first-page":"2958","article-title":"A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagen.2023.130414_bb0020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2012.02.063","article-title":"Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization","volume":"149","author":"Shan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbagen.2023.130414_bb0025","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/ijc.32499","article-title":"Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab","volume":"146","author":"Kim","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbagen.2023.130414_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03992.x","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy","volume":"158","author":"Martinelli","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbagen.2023.130414_bb0035","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/med.21488","article-title":"Targeting EGFRL858R\/T790M and EGFRL858R\/T790M\/C797S resistance mutations in NSCLC: current developments in medicinal chemistry","volume":"38","author":"Lu","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbagen.2023.130414_bb0040","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","article-title":"Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition","volume":"19","author":"Holmes","year":"2007","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbagen.2023.130414_bb0045","doi-asserted-by":"crossref","first-page":"10797","DOI":"10.1021\/jm301085w","article-title":"Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors","volume":"55","author":"Musumeci","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mvr.2008.01.002","article-title":"Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells","volume":"76","author":"Amin","year":"2008","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.bbagen.2023.130414_bb0055","first-page":"5879","article-title":"Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3\u2032-kinase and distinct from that induced by hypoxia","volume":"60","author":"Maity","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2023.130414_bb0060","series-title":"The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease","first-page":"1","author":"Aggarwal","year":"2007"},{"key":"10.1016\/j.bbagen.2023.130414_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1476-4598-10-12","article-title":"Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma","volume":"10","author":"Wilken","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbagen.2023.130414_bb0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cbi.2008.05.003","article-title":"Antioxidant and radical scavenging properties of curcumin","volume":"174","author":"Ak","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bbagen.2023.130414_bb0075","series-title":"The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease","first-page":"173","author":"Kuttan","year":"2007"},{"key":"10.1016\/j.bbagen.2023.130414_bb0080","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/BF03401744","article-title":"Curcumin is an in vivo inhibitor of angiogenesis","volume":"4","author":"Arbiser","year":"1998","journal-title":"Mol. Med."},{"key":"10.1016\/j.bbagen.2023.130414_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/107555303321223035","article-title":"Safety and anti-inflammatory activity of curcumin: A component of Tumeric (Curcuma longa)","volume":"9","author":"Chainani-Wu","year":"2003","journal-title":"J. Altern. Complement. Med."},{"key":"10.1016\/j.bbagen.2023.130414_bb0090","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of curcumin: problems and promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbagen.2023.130414_bb0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejmech.2019.04.058","article-title":"Developments in the anticancer activity of structurally modified curcumin: an up-to-date review","volume":"177","author":"Rodrigues","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0100","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0731-7085(96)02024-9","article-title":"Stability of curcumin in buffer solutions and characterization of its degradation products","volume":"15","author":"Wang","year":"1997","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbagen.2023.130414_bb0105","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ejmech.2014.07.053","article-title":"Synthesis and biological evaluation of novel 6-chloroquinazolin derivatives as potential antitumor agents","volume":"84","author":"Luo","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0110","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1021\/acs.jmedchem.5b00470","article-title":"Structure-activity relationship and pharmacokinetic studies of 1,5-Diheteroarylpenta-1,4-dien-3-ones: A class of promising curcumin-based anticancer agents","volume":"58","author":"Wang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejmech.2014.01.041","article-title":"Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents","volume":"75","author":"Samaan","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0120","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejmech.2016.12.043","article-title":"Synthesis and biological evaluation of curcumin inspired indole analogues as tubulin polymerization inhibitors","volume":"127","author":"Sri Ramya","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejmech.2017.11.010","article-title":"Synthesis and biological evaluation of curcumin inspired imidazo[1,2-a]pyridine analogues as tubulin polymerization inhibitors","volume":"143","author":"Ramya","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0130","doi-asserted-by":"crossref","first-page":"33963","DOI":"10.1021\/acsomega.2c02933","article-title":"Synthesis, biological evaluation, and molecular modeling studies of 1-aryl-1H-Pyrazole-fused curcumin analogues as anticancer agents","volume":"7","author":"Nam","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbagen.2023.130414_bb0135","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1016\/j.bmc.2013.06.053","article-title":"Exploring pyrimidine-substituted curcumin analogues: design, synthesis and effects on EGFR signaling","volume":"21","author":"Qiu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.biopha.2016.11.040","article-title":"In silico and In vitro anti-cancer potential of a curcumin analogue (1E,6E)-1,7-di(1H-indol-3-yl)hepta-1,6-diene-3,5-dione","volume":"85","author":"Sufi","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbagen.2023.130414_bb0145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bmc.2012.11.031","article-title":"Design, synthesis and molecular docking of \u03b1,\u03b2-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity","volume":"21","author":"Xu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/cbdd.12964","article-title":"Synthesis and mechanistic studies of curcumin analog-based oximes as potential anticancer agents","volume":"90","author":"Qin","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bbagen.2023.130414_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103470","article-title":"Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line","volume":"97","author":"Bennani","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1389557521666210325115218","article-title":"Recent Progress in anticancer agents incorporating Pyrazole scaffold","volume":"22","author":"Mor","year":"2022","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0165","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.4067\/S0717-97072020000104746","article-title":"Pyrazole bearing molecules as bioactive scaffolds: A review","volume":"65","author":"Aziz","year":"2020","journal-title":"J. Chil. Chem. Soc."},{"key":"10.1016\/j.bbagen.2023.130414_bb0170","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2023.130414_bb0175","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.bmcl.2009.01.006","article-title":"Synthesis and antimicrobial activity of some new pyrazole derivatives containing a ferrocene unit","volume":"19","author":"Damljanovi\u0107","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbagen.2023.130414_bb0180","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ejmech.2015.07.031","article-title":"Design, synthesis and biological evaluation of 1,3-diphenyl-1H-pyrazole derivatives containing benzimidazole skeleton as potential anticancer and apoptosis inducing agents","volume":"101","author":"Reddy","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112161","article-title":"Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B\/JARID1B)","volume":"192","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmech.2016.03.051","article-title":"Synthesis of (Z)-1-(1,3-diphenyl-1H-pyrazol-4-yl)-3-(phenylamino)prop-2-en-1-one derivatives as potential anticancer and apoptosis inducing agents","volume":"117","author":"Srinivasa Reddy","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0195","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1016\/j.bmc.2016.08.002","article-title":"Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK","volume":"24","author":"Lv","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bmcl.2015.12.007","article-title":"Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: design, synthesis and SAR study","volume":"26","author":"Wen","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbagen.2023.130414_bb0205","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejmech.2013.10.077","article-title":"Design and synthesis of pyrazole-oxindole conjugates targeting tubulin polymerization as new anticancer agents","volume":"92","author":"Kamal","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0210","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejmech.2015.02.018","article-title":"Synthesis, biological evaluation and 3D-QSAR studies of novel 5-phenyl-1H-pyrazol cinnamamide derivatives as novel antitubulin agents","volume":"93","author":"Wang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0215","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejmech.2016.09.002","article-title":"Pyrazole-based potent inhibitors of GGT1: synthesis, biological evaluation, and molecular docking studies","volume":"124","author":"Mansha","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0220","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1016\/j.bmc.2016.05.032","article-title":"Synthesis and biological activity of pyrazole analogues of the staurosporine aglycon K252c","volume":"24","author":"Esvan","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0225","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1016\/j.bmc.2015.05.052","article-title":"5-aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII","volume":"23","author":"Cvijeti\u0107","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0230","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/1573409916666200520083215","article-title":"Molecular docking studies of glycyrrhetinic acid derivatives as anti- colorectal cancer agents","volume":"17","author":"Nam","year":"2021","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.bbagen.2023.130414_bb0235","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bmcl.2015.11.040","article-title":"Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR\/HER-2 kinase inhibitors","volume":"26","author":"Tao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbagen.2023.130414_bb0240","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.bmc.2012.01.051","article-title":"Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors","volume":"20","author":"Qiu","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0245","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bmcl.2007.12.035","article-title":"Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors","volume":"18","author":"Ducray","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbagen.2023.130414_bb0250","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bioorg.2018.03.002","article-title":"Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors","volume":"78","author":"Akhtar","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0255","doi-asserted-by":"crossref","first-page":"11429","DOI":"10.1038\/s41598-020-68134-8","article-title":"Design, synthesis, structure, in vitro cytotoxic activity evaluation and docking studies on target enzyme GSK-3\u03b2 of new indirubin-3\u2032-oxime derivatives","volume":"10","author":"Dan","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbagen.2023.130414_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130414_bb0265","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagen.2023.130414_bb0270","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbagen.2023.130414_bb0275","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2144\/03355pf01","article-title":"DEVDase detection in intact apoptotic cells using the cell permeant fluorogenic substrate, (z-DEVD)-2-cresyl violet","volume":"35","author":"Lee","year":"2003","journal-title":"BioTechniques"},{"key":"10.1016\/j.bbagen.2023.130414_bb0280","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagen.2023.130414_bb0285","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/616149","article-title":"The role of intrinsic pathway in apoptosis activation and progression in Peyronie\u2019s disease","volume":"2014","author":"Loreto","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbagen.2023.130414_bb0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-4598-8-8","article-title":"Centrosome-associated regulators of the G2\/M checkpoint as targets for cancer therapy","volume":"8","author":"Wang","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbagen.2023.130414_bb0295","doi-asserted-by":"crossref","first-page":"46877","DOI":"10.1074\/jbc.M207902200","article-title":"Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione","volume":"277","author":"Pu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0300","doi-asserted-by":"crossref","first-page":"20267","DOI":"10.1074\/jbc.M312381200","article-title":"Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells","volume":"279","author":"Chao","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-9966-30-33","article-title":"Osthole induces G2\/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K\/Akt pathway","volume":"30","author":"Xu","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbagen.2023.130414_bb0310","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/md11020316","article-title":"Asperolide A, a marine-derived Tetranorditerpenoid, induces G2\/M arrest in human NCI-H460 lung carcinoma cells, is mediated by p53-p21 stabilization and modulated by Ras\/Raf\/MEK\/ERK signaling pathway","volume":"11","author":"Lv","year":"2013","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bbagen.2023.130414_bb0315","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbagen.2023.130414_bb0320","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbagen.2023.130414_bb0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbagen.2023.130414_bb0330","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1016\/j.bmcl.2009.08.045","article-title":"Using the Golden triangle to optimize clearance and oral absorption","volume":"19","author":"Johnson","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbagen.2023.130414_bb0335","first-page":"8","article-title":"Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions","volume":"1","author":"Ertl","year":"2009","journal-title":"Aust. J. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0340","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0345","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical drug properties associated with in vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbagen.2023.130414_bb0350","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jm701122q","article-title":"Generation of a set of simple, interpretable ADMET rules of thumb","volume":"51","author":"Gleeson","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0355","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock 4 and AutoDock tools 4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0360","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3390\/molecules23051038","article-title":"Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data?","volume":"23","author":"Ram\u00edrez","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bbagen.2023.130414_bb0365","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbagen.2023.130414_bb0370","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bmcl.2013.10.003","article-title":"Drug discovery considerations in the development of covalent inhibitors","volume":"24","author":"Mah","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbagen.2023.130414_bb0375","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0380","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65824","article-title":"Structural basis of the effect of activating mutations on the EGF receptor","volume":"10","author":"Galdadas","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.bbagen.2023.130414_bb0385","series-title":"Cancer Cell Culture: Methods and Protocols","first-page":"237","author":"Van Meerloo","year":"2011"},{"key":"10.1016\/j.bbagen.2023.130414_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2019.00917","article-title":"Novel anticancer fused Pyrazole derivatives as EGFR and VEGFR-2 dual TK inhibitors","volume":"7","author":"Saleh","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116168","article-title":"Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2 TK inhibition","volume":"40","author":"Hassan","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0400","first-page":"158","article-title":"Assignment of DNA binding sites for 4\u2032,6-diamidine-2-phenylindole and bisbenzimide (Hoechst 33258). A comparative footprinting study","volume":"949","author":"Portugal","year":"1988","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"10.1016\/j.bbagen.2023.130414_bb0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bbagen.2023.130414_bb0410","first-page":"2597","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bbagen.2023.130414_bb0415","doi-asserted-by":"crossref","first-page":"9357","DOI":"10.1074\/jbc.273.16.9357","article-title":"Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis","volume":"273","author":"J\u00e4nicke","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2023.130414_bb0420","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0248-4900(93)90110-Z","article-title":"Cell cycle analysis by flow cytometry: principles and applications","volume":"78","author":"Jayat","year":"1993","journal-title":"Biol. Cell."}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416523001125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416523001125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:18:45Z","timestamp":1759637925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416523001125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0304416523001125"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2023.130414","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, in vitro and in silico evaluation of anti-colorectal cancer activity of curcumin analogues containing 1,3-diphenyl-1H-pyrazole targeting EGFR tyrosine kinase","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2023.130414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"130414"}}